| 12215113 |
Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide] |
Satish Puppali, James T. Palmer, Thorsten A. Kirschberg, Angelina Sau Man Wong, Jay Li +9 more |
2025-02-04 |
| 12018032 |
Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
Priyanka Somanath, Daniel C. Lu, Taisei Kinoshita, Brian Keith Law, Thomas Butler +5 more |
2024-06-25 |
| 10828259 |
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Ching Wah Chong, Robert Kuehl, Harisha Atluri |
2020-11-10 |
| 10213386 |
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Ching Wah Chong, Robert Kuehl, Harisha Atluri |
2019-02-26 |
| 10010507 |
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Ching Wah Chong, Robert Kuehl, Harisha Atluri |
2018-07-03 |
| 9655857 |
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Ching Wah Chong, Robert Kuehl, Harisha Atluri |
2017-05-23 |